PRODOTTO NON ANCORA VALIDATO
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Utilizza questo identificativo per citare o creare un link a questo documento:
|Titolo:||Analisi economica dei costi e dei benefici dell'implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in italia|
|Data di pubblicazione:||2009|
|Autori interni:||TARRICONE, ROSANNA|
|Autori:||R Tarricone; C Giaquinto; N Largeron; M Trichard|
|Rivista:||PHARMACOECONOMICS, ITALIAN RESEARCH ARTICLES|
|Abstract:||Background. The economic burden of rotavirus gastroenteritis (RVGE) to society is high as shown from results of recent European studies. The evidence suggests that the implementation of anti-rotavirus vaccination programs can substantially decrease costs thus freeing resources for alternative uses. The objective of this study was to measure the health benefits and costs of a pentavalent vaccination programme in Italy. Methods. A decision model was designed to follow a cohort of infants from birth to 5 years of age. Input data were mainly drawn from a recent prospective observational study (REVEAL) conducted in seven European regions including one in Italy that recorded healthcare utilisation for children under five with acute gastroenteritis. Results. The implementation of a pentavalent anti-rotavirus vaccination (80% coverage rate) would avoid 61 704 cases of RVGE seeking healthcare; 42 368 GP and paediatricians’ consultations; 38 304 emergency visits; 10 673 hospitalizations; 2 327 nosocomial infections; and 7 deaths. It would also avoid 217 596 lost working days for parents. From the national health system perspective, the cost of the programme would be €48.5 million and the reduction in the cost of disease would be €20.6 million (-72%). From the societal perspective, the programme would reduce the global cost of disease by €56.4 million (-70%) resulting in a net benefit of €7.8 million. Conclusions. Today prevention is at the top of policy-makers’ agendas in all western countries. There is a wealth of evidence on the economic and clinical benefits from vaccination programmes against RVGE. The present study confirms previous results thus suggesting that the vaccination programme should be implemented in Italy.|
|Appare nelle tipologie:||01 - Articolo su rivista Scientifica|
File in questo prodotto:
Non ci sono file associati a questo prodotto.
- PubMed Central loading...
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.